A Phase 2/3 interventional study of GS-3242 Tablet and GS-3242 Injection in HIV-1-infection, sponsored by Gilead Sciences. Recruiting at 21 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Gilead Sciences · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study will have two portions: Phase 2 and Phase 3. Phase 2 will further have 2 parts: Part A and Part B.
The goal of Phase 2, Part A is to assess the effectiveness of study drugs GS-3242 plus Lenacapavir (LEN) versus Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)), in people with HIV-1 (PWH) who are new to treatment. This will be done in Treatment Groups 1, 2 and 3 at Week 35.
The goal of Phase 2, Part B is to compare the effectiveness of study drugs, GS-3242 and LEN versus B/F/TAF in Groups 4 and 3 at Week 26.
The goal of Phase 3 is to assess the long-term effectiveness of study drug GS-3242 and LEN versus B/F/TAF, at Week 52.
The primary objectives of this study are:
Phase 2, Part A: To evaluate the efficacy of intramuscular (IM) GS-3242 plus IM LEN versus B/F/TAF in treatment-naive people with HIV-1 (PWH) in Treatment Groups 1, 2, and 3 at Week 35. Phase 2, Part B: To evaluate the efficacy of IM GS-3242 plus IM LEN versus B/F/TAF in treatment-naive PWH in Treatment Groups 4 and 3 at Week 26.
Phase 3: To evaluate the efficacy of IM GS-3242 plus IM LEN versus B/F/TAF in treatment-naive PWH at Week 52.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized to receive oral loading doses of GS-3242 in combination with LEN oral tablets, followed by intramuscular (IM) injections of GS-3242 and LEN for at least 52 weeks.
Drug: GS-3242 Tablet · Drug: GS-3242 Injection · Drug: Lenacapavir Tablet · Drug: Lenacapavir Injection
Participants will be randomized oral loading doses of GS-3242 in combination with LEN oral tablets, followed by IM injections of GS-3242 (at a different dose than Group 1) and LEN for at least 52 weeks.
Drug: GS-3242 Tablet · Drug: GS-3242 Injection · Drug: Lenacapavir Tablet · Drug: Lenacapavir Injection
Participants will be randomized to receive 50/200/25 mg of B/F/TAF daily for at least 52 weeks.
Drug: B/F/TAF
Participants will be enrolled (non-randomized) to receive oral loading doses of GS-3242 in combination with LEN oral tablets, followed IM injections of GS-3242 and LEN (at different doses than Group 1 and 2) for at least 52 weeks.
Drug: GS-3242 Tablet · Drug: GS-3242 Injection · Drug: Lenacapavir Tablet · Drug: Lenacapavir Injection
Participants will be randomized to receive oral loading doses of GS-3242 in combination with LEN oral tablets, followed by IM injections of GS-3242 and LEN for at least 104 weeks.
Drug: GS-3242 Tablet · Drug: GS-3242 Injection · Drug: Lenacapavir Tablet · Drug: Lenacapavir Injection
Participants will be randomized to receive 50/200/25 mg of B/F/TAF daily for at least 104 weeks.
Drug: B/F/TAF
Administered orally
Administered intramuscularly (IM)
Administered orally
Also known as: LEN
Administered IM
Also known as: LEN
Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide
Administered orally
Also known as: Biktarvy
Phase 2: Part A: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 35 as Determined by the United States (US) Food and Drug Administration (FDA) Snapshot Algorithm
Time frame: Week 35
Phase 2: Part B: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 26 as Determined by the US FDA Snapshot Algorithm
Time frame: Week 26
Phase 3: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 52 as Determined by the US FDA Snapshot Algorithm
Time frame: Week 52
Phase 2: Parts A and B: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 as Determined by the US FDA Snapshot Algorithm
Time frame: Week 12
Phase 2: Parts A and B: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 52 as Determined by the US FDA Snapshot Algorithm
Time frame: Week 52
Phase 2: Parts A and B: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 12
Time frame: Baseline, Week 12
Phase 2: Part A: Change From Baseline in CD4 Cell Count at Week 35
Time frame: Baseline, Week 35
Phase 2: Parts A and B: Change From Baseline in CD4 Cell Count at Week 52
Time frame: Baseline, Week 52
Phase 2: Part B: Change From Baseline in CD4 Cell Count at Week 26
Time frame: Baseline, Week 26
Phase 2: Parts A and B: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) Through Week 12
Time frame: From first dose date up to Week 12
Phase 2: Part A: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 35
Time frame: Week 35
Phase 2: Part B: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 26
Time frame: From first dose date up to Week 26
Phase 2: Parts A and B and Phase 3: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 52
Time frame: From first dose date up to Week 52
Phase 2: Part A: Groups 1 and 2: Trough Concentrations of GS-3242 and LEN at Week 18
Time frame: Week 18
Phase 2: Part A: Groups 1 and 2: Trough Concentrations of GS-3242 and LEN at Week 35
Time frame: Week 35
Phase 2: Part A and Part B: Trough Concentrations of GS-3242 and LEN at Week 52
Time frame: Week 52
Phase 2: Part B: Trough Concentrations of GS-3242 and LEN at Week 26
Time frame: Week 26
Phase 3: Proportion of Participants with HIV-1 RNA < 50 copies/mL at Week 104 as determined by the US FDA snapshot algorithm
Time frame: Week 104
Phase 3: Change From Baseline in CD4 Cell Count at Week 52
Time frame: Baseline, Week 52
Phase 3: Change From Baseline in CD4 Cell Count at Week 104
Time frame: Baseline, Week 104
Phase 3: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 52
Time frame: From first dose up to Week 52
Phase 3: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 104
Time frame: From first dose up to Week 104
Plan to share: No
Started Jul 2026 (actual). Primary completion is estimated for Oct 2030, 51 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: GS-3242 · Lenacapavir · Bictegravir · Emtricitabine · Tenofovir alafenamide